comparemela.com

Latest Breaking News On - Endpoints - Page 10 : comparemela.com

Glaukos Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials of iDose TR, Achieving Primary Efficacy Endpoints and Demonstrating Favorable Tolerability and Safety Profiles

Phase 3 Pivotal Trials Met Pre-Specified Primary Efficacy Endpoints for Both Doses of iDose TR , Supporting Anticipated Upcoming NDA Submission 93% of Slow-Release iDose TR Subjects Remained. | September 7, 2022

Thomas burnsGlaukos corporationDrug administrationMicro invasive glaucoma surgeryGlaukos corporation stock exchangePress releaseUbjects gkos us3773221029

Futura Medical plc: Highly positive FM71 Phase 3 study results with all primary and secondary endpoints achieved, MED3000 remains on track to submit for FDA marketing authorization

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys drug delivery technology and currently focused on

United statesUnited kingdomCity ofKen jamesErich sandovalDaniel popoloskiJames barderAngela hildrethLondon stock exchangeDrug administrationInvestor centreEfficacy coFutura medicalChief executive officerExecutive directorAfrican americans

Medtronic Says Extravascular ICD Meets Clinical Trial s Safety And Effectiveness Endpoints

FRIDLEY (dpa-AFX) - Medtronic plc (MDT) said that its investigational EV ICD System - a defibrillator with the lead placed under the breastbone, outside of the heart and veins - achieved a defibrillation

More such health news

HitGen Inc : OpenDEL3 0 - DRUG DISCOVERY PARTNER webinar offered by HitGen and Endpoints News coming up on Thursday 4th August

CHENGDU, China, Aug. 2, 2022 /PRNewswire/ "OpenDEL3.0 - DRUG DISCOVERY PARTNER" webinar will be jointly held by HitGen Inc. and Endpoints News on Thursday 4th August, to present you with

Kostenloser wertpapierhandelGuansai liuPrnewswire openZhujun yaoUniversity of scienceHitgen incGeorgia state universityDiscovery chemistry unit at hitgen incTechnology of chinaEndpoints newsExecutive directorDiscovery chemistry unitKey featuresProfessor zhujun yao

Novo Nordisk ONWARDS 3 and 4 Trials Achieve Primary Endpoints

(PLX AI) - Novo Nordisk achieves primary objectives of ONWARDS 3 and 4 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin degludec in ONWARDS 3.• Novo Nordisk trial

Novo nordisk

vimarsana © 2020. All Rights Reserved.